Nasdaq · Healthcare
ZEVRA THERAPEUTICS, INC. (ZVRA)
As-reported financials and recent SEC filings for ZEVRA THERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$106.5M
Net income
$83.2M
Net margin
78.2%
Diluted EPS
$1.35
ROE
53.8%
P/E (TTM)
—
Market cap
—
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.6M |
| Gross profit | — | — | $24.5M | — | — |
| Operating income | $-62.9M | $-87.0M | $-49.6M | $-42.6M | $7.7M |
| Net income | $83.2M | $-105.5M | $-46.0M | $-26.8M | $-8.6M |
| Diluted EPS | $1.35 | $-2.28 | — | — | $-2.11 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →8-K2026-06-05
View on EDGAR →Largest Healthcare peers
Go deeper on ZVRA
Search ZEVRA THERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.